Humana (NYSE:HUM) Stock Price Down 2.7%

Humana Inc. (NYSE:HUM)’s stock price was down 2.7% during mid-day trading on Wednesday . The stock traded as low as $362.78 and last traded at $364.86. Approximately 289,561 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,805,654 shares. The stock had previously closed at $374.82.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of research analyst reports. UBS Group lowered their target price on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. Barclays reduced their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd. Baird R W upgraded shares of Humana to a “hold” rating in a report on Thursday, May 30th. Oppenheimer decreased their target price on Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Finally, Jefferies Financial Group cut their price target on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a report on Monday, April 22nd. Fourteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $409.55.

Humana Stock Down 3.2 %

The company has a market cap of $43.72 billion, a P/E ratio of 22.59, a PEG ratio of 2.10 and a beta of 0.51. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm has a fifty day moving average price of $347.65 and a 200 day moving average price of $349.45.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the company posted $9.38 EPS. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities research analysts forecast that Humana Inc. will post 16.27 earnings per share for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 0.98%. Humana’s payout ratio is presently 22.04%.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently modified their holdings of HUM. Rakuten Securities Inc. acquired a new stake in shares of Humana during the fourth quarter worth $25,000. Gradient Investments LLC increased its stake in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares in the last quarter. Cetera Trust Company N.A acquired a new stake in Humana in the fourth quarter worth $28,000. Private Wealth Management Group LLC bought a new position in shares of Humana during the fourth quarter worth $32,000. Finally, Carolinas Wealth Consulting LLC grew its holdings in shares of Humana by 274.1% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after buying an additional 74 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.